Recursion Pharmaceuticals (RXRX) EBT Margin (2020 - 2026)
Recursion Pharmaceuticals (RXRX) posted EBT Margin of 1886.71% for Q1 2026, down 520.25% on a QoQ basis from 304.19% in Q4 2025, and down 51238.0% year-over-year from N/an in Q1 2025.
Recursion Pharmaceuticals (RXRX) EBT Margin (2020 - 2026) Analysis & Trends
Recursion Pharmaceuticals' EBT Margin history runs 7 years deep, the most recent figure standing at 1886.71% for Q1 2026.
- Quarterly EBT Margin fell 51238.0% year-over-year to 1886.71% in Q1 2026, while the trailing twelve-month figure through Mar 2026 was 849.83% (up 11234.0% YoY) and the FY2025 annual result came in at 863.53%, down 7360.0% from the prior year.
- EBT Margin was 1886.71% for Q1 2026 at Recursion Pharmaceuticals, down from 304.19% in the prior quarter.
- Across five years, EBT Margin topped out at 304.19% in Q4 2025 and bottomed at 3935.31% in Q4 2024.
- A 5-year average of 1124.38% and a median of 862.72% in 2022 frame the typical range for EBT Margin.
- Annual changes were most pronounced in 2024 — EBT Margin tumbled 304413 bps — and 2025, when it soared 363112 bps.
- Recursion Pharmaceuticals' EBT Margin stood at 471.92% in 2022, then sank by 89 bps to 891.18% in 2023, then slumped by 342 bps to 3935.31% in 2024, then surged by 92 bps to 304.19% in 2025, then slumped by 520 bps to 1886.71% in 2026.
- Business Quant data shows RXRX's EBT Margin at 1886.71% in Q1 2026, 304.19% in Q4 2025, and 3135.27% in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBT Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | - |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | 17.13% |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | - |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | 41.95% |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | 23.05% |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | 34.77% |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | - |
| 10 | Recursion Pharmaceuticals | 1.59 Bn | 933.22 Mn | -6.02 Mn | -1,886.71% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -1,886.71% |
| Dec 31, 2025 | -304.19% |
| Sep 30, 2025 | -3,135.27% |
| Jun 30, 2025 | -894.23% |
| Mar 31, 2025 | -1,374.33% |
| Dec 31, 2024 | -3,935.31% |
| Sep 30, 2024 | -366.82% |
| Jun 30, 2024 | -680.19% |
| Mar 31, 2024 | -668.06% |
| Dec 31, 2023 | -891.18% |
| Sep 30, 2023 | -883.10% |
| Jun 30, 2023 | -696.43% |
| Mar 31, 2023 | -538.38% |
| Dec 31, 2022 | -471.92% |
| Sep 30, 2022 | -475.58% |
| Jun 30, 2022 | -862.72% |
| Mar 31, 2022 | -1,049.97% |
| Dec 31, 2021 | -2,565.14% |
| Sep 30, 2021 | -1,839.86% |
| Jun 30, 2021 | -1,703.81% |